SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on October 14, 2009. The registrant is incorporated in Colorado and is headquartered in Castle Rock, Colorado. The filing reports the closing of a previously announced equity offering.
Key Financial Metrics
The filing details a capital raise event rather than operational financial performance. Key metrics include:
- Shares Issued: 5,155,000 shares of common stock.
- Over-Allotment: The underwriter exercised its option in full to purchase 672,391 additional shares.
- Net Proceeds: Approximately $8.3 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Use of Proceeds: Product development, FDA 510(k) submission activities, general corporate purposes, and working capital.
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in the company's equity capitalization and cash reserves resulting from the closing of the offering. The total share count increased by 5,155,000 shares compared to the pre-offering state.
Outlook and Management Commentary
Management indicated that the net proceeds will be strategically allocated to advance product development and regulatory submissions (specifically FDA 510(k)). The filing does not contain forward-looking guidance on future revenue or earnings, nor does it detail specific risks or contingencies beyond the standard nature of product development.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-offering to assess dilution impact.
- Confirm the specific timeline for the FDA 510(k) submission mentioned as a use of proceeds.
- Review the full press release (Exhibit 99.1) for details on the underwriting agreement and specific offering expenses.
- Check subsequent filings for updates on the deployment of the $8.3 million in net proceeds.